Neuroimmunological mechanism of morphine tolerance in cancer pain

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2000028908

Enrollment

Unknown

Registered

2020-01-07

Start date

2019-03-07

Completion date

Unknown

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer pain

Interventions

Cancer pain patients morphine tolerance group:Nil

Normal control group:Nil

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) Patients with various types of cancer undergoing IDD surgery; (2) Analgesics currently used are converted to> 60mg / 24 hours morphine orally as morphine tolerance; (3) Aged > 18 years; (4) Can understand the experiment Content and voluntary test; (5) The subject (or his designated agent) must sign the informed consent;

Exclusion criteria

Exclusion criteria: (1) Presence of central nervous system infection; (2) People with central tumor metastasis; (3) Serious mental or cognitive impairment.

Design outcomes

Primary

Measure	Time frame
PHQ-9;Lipocalin-2;IL-6;BDNF;Netrin-1;NRS Score;ID-pain;GAD-7;	—

Countries

China

Contacts

Public ContactLina Wang

The First Affiliated Hospital of Suzhou University

wangln@suda.edu.cn+86 13915400622

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026